Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

Form 6-K

 

 

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

 

For the month of June, 2022

 

Commission File Number: 001-41106

 

 

 

Incannex Healthcare Limited

(Exact name of Registrant as specified in its charter)

 

 

 

not applicable

(Translation of Registrant’s name into English)

 

Australia

(Jurisdiction of incorporation or organization)

 

Joel Latham

Chief Executive Officer and Managing Director

Level 39, Rialto South Tower
525 Collins Street

Melbourne 3000

Australia

(Address of principal executive offices)

 

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F:

 

Form 20-F ☒ Form 40-F ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

 

Yes ☐  No ☒

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

 

Yes ☐  No ☒

 

 

 

 

 

 

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

  

On June 03, 2022, Incannex Healthcare Limited filed with the Australian Securities Exchange an announcement captioned “Positive final results from IHL-42X phase 2 trial”, a copy of which announcement is attached to this Form 6-K as Exhibit 99.1.

 

On June 03, 2022, Incannex Healthcare Limited filed with the Australian Securities Exchange an announcement captioned “IHL-42X phase 2 clinical trial presentation”, a copy of which announcement is attached to this Form 6-K as Exhibit 99.2.

 

1

 

 

Signatures

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	Incannex Healthcare Limited
Date: June 03, 2022	By:	/s/ Joel Latham
	Name:	Joel Latham
	Title:	Chief Executive Officer and Managing Director

 

2

 

 

INDEX TO EXHIBITS

 

Exhibit No.
99.1		ASX Announcement, dated June 03, 2022 – Positive final results from IHL-42X phase 2 trial
99.2		ASX Announcement, dated June 03, 2022 – IHL-42X phase 2 clinical trial presentation

 

 

3